ascopubs.org29d
Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024). LITESPARK-005, KEYNOTE-564, TIVO-3, CLEAR, CHECKMATE-9ER, ...